A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors.
Milojkovic Kerklaan B, Slater S, Flynn M, Greystoke A, Witteveen PO, Megui-Roelvink M, de Vos F, Dean E, Reyderman L, Ottesen L, Ranson M, Lolkema MP, Plummer R, Kristeleit R, Evans TR, Schellens JH.
Milojkovic Kerklaan B, et al. Among authors: ranson m.
Invest New Drugs. 2016 Jun;34(3):329-37. doi: 10.1007/s10637-016-0344-9. Epub 2016 Apr 2.
Invest New Drugs. 2016.
PMID: 27039386
Clinical Trial.